Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.6667.

Several equities analysts have recently commented on the stock. Piper Sandler increased their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Finally, Wall Street Zen raised Acrivon Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday.

Insider Activity

In other Acrivon Therapeutics news, CEO Peter Blume-Jensen purchased 49,000 shares of Acrivon Therapeutics stock in a transaction dated Wednesday, January 14th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $82,320.00. Following the transaction, the chief executive officer owned 2,095,771 shares in the company, valued at $3,520,895.28. This represents a 2.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have bought 67,832 shares of company stock valued at $114,534. Company insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG lifted its holdings in Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after acquiring an additional 682,763 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Acrivon Therapeutics by 1.7% in the 4th quarter. Renaissance Technologies LLC now owns 634,169 shares of the company’s stock worth $1,528,000 after purchasing an additional 10,769 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics by 231.4% in the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock worth $1,196,000 after purchasing an additional 346,366 shares during the last quarter. Jane Street Group LLC boosted its position in Acrivon Therapeutics by 18.3% during the 4th quarter. Jane Street Group LLC now owns 342,071 shares of the company’s stock valued at $824,000 after purchasing an additional 52,823 shares during the period. Finally, Two Sigma Investments LP grew its stake in Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares during the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $1.50 on Tuesday. The company has a market capitalization of $47.34 million, a price-to-earnings ratio of -0.70 and a beta of 1.74. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $5.96. The company’s fifty day moving average price is $1.99 and its two-hundred day moving average price is $1.90.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.